These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 8407122)
1. The use of tissue plasminogen activator in postvitrectomy cases. Koutsandrea C; Apostolopoulos M; Theodossiadis P Int Ophthalmol; 1993 Apr; 17(2):95-100. PubMed ID: 8407122 [TBL] [Abstract][Full Text] [Related]
2. Tissue plasminogen activator for postvitrectomy fibrin formation. Jaffe GJ; Abrams GW; Williams GA; Han DP Ophthalmology; 1990 Feb; 97(2):184-9. PubMed ID: 2109297 [TBL] [Abstract][Full Text] [Related]
3. [Treatment of intraocular fibrin formation with tissue plasminogen activator after vitrectomy]. Zhao P; Wang W Zhonghua Yan Ke Za Zhi; 1995 Jul; 31(4):255-8. PubMed ID: 8745515 [TBL] [Abstract][Full Text] [Related]
4. Treatment of postvitrectomy fibrin pupillary block with tissue plasminogen activator. Jaffe GJ; Lewis H; Han DP; Williams GA; Abrams GW Am J Ophthalmol; 1989 Aug; 108(2):170-5. PubMed ID: 2502924 [TBL] [Abstract][Full Text] [Related]
5. Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator. Williams GA; Lambrou FH; Jaffe GA; Snyder RW; Green GD; Devenyi RG; Abrams GW Arch Ophthalmol; 1988 Aug; 106(8):1055-8. PubMed ID: 3135790 [TBL] [Abstract][Full Text] [Related]
12. Topical treatment of postvitrectomy fibrin formation with tissue plasminogen activator. Cellini M; Baldi A; Possati GL Int Ophthalmol; 1994-1995; 18(6):351-3. PubMed ID: 7642335 [TBL] [Abstract][Full Text] [Related]
13. Tissue plasminogen activator in the treatment of vitreoretinal diseases. Kamei M; Estafanous M; Lewis H Semin Ophthalmol; 2000 Mar; 15(1):44-50. PubMed ID: 10749314 [TBL] [Abstract][Full Text] [Related]
14. Effect of immediate postoperative intracameral tissue plasminogen activator (tPA) on anterior chamber fibrin formation in dogs undergoing phacoemulsification. Mancuso LA; Nadelstein B; Berdoulay A; Spatola RA Vet Ophthalmol; 2019 Jul; 22(4):477-484. PubMed ID: 30773778 [TBL] [Abstract][Full Text] [Related]
15. The use of recombinant tissue plasminogen activator for intracameral fibrinolysis following cataract surgery. Wedrich A; Menapace R; Mühlbauer-Ries E Int Ophthalmol; 1994-1995; 18(5):277-80. PubMed ID: 7607808 [TBL] [Abstract][Full Text] [Related]
16. Tissue plasminogen activator treatment of postoperative intraocular fibrin. Johnson RN; Olsen K; Hernandez E Ophthalmology; 1988 May; 95(5):592-6. PubMed ID: 3140157 [TBL] [Abstract][Full Text] [Related]
17. Treatment of total hyphema with relatively low-dose tissue plasminogen activator. Kim MH; Koo TH; Sah WJ; Chung SM Ophthalmic Surg Lasers; 1998 Sep; 29(9):762-6. PubMed ID: 9760614 [TBL] [Abstract][Full Text] [Related]
18. Intraocular recombinant tissue-plasminogen activator fibrinolysis of fibrin formation after cataract surgery in children. Klais CM; Hattenbach LO; Steinkamp GW; Zubcov AA; Kohnen T J Cataract Refract Surg; 1999 Mar; 25(3):357-62. PubMed ID: 10079440 [TBL] [Abstract][Full Text] [Related]
19. Intracameral tissue plasminogen activator use in a large series of eyes with valved glaucoma drainage implants. Zalta AH; Sweeney CP; Zalta AK; Kaufman AH Arch Ophthalmol; 2002 Nov; 120(11):1487-93. PubMed ID: 12427061 [TBL] [Abstract][Full Text] [Related]